Recruiting

Domperidone

Sponsor:

Jose Cocjin

Code:

NCT04699591

Conditions

GERD

Gastroesophageal Reflux

Gastroparesis

Eligibility Criteria

Sex: All

Age: 12 - 21

Healthy Volunteers: Not accepted

Interventions

Domperidone

Study Details

Brief summary:

The purpose of this program is to allow the use of domperidone in children from 12 to 21 years of age with symptoms related to motility disorders and Gastroesophageal reflux disease (GERD) who have failed all the standard treatments for their condition.

Conditions

GERD

Gastroesophageal Reflux

Gastroparesis

Study ID

NCT04699591

Start date

Apr, 2013

Status verified date

Mar, 2026

Completion date

Dec, 2035

Anticipated

Primary completion date

Dec, 2035

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12 - 21

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Male or female
2. Age 12 - 21
3. Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation that are refractory to standard therapy.
4. Patients must have a comprehensive evaluation to eliminate other causes of their symptoms.
5. Patient has signed informed consent for the administration of domperidone that informs the patient of potential adverse events including:

  • increased prolactin levels
  • extrapyramidal side effects
  • breast changes
  • Cardiac arrhythmias including QT prolongation
  • There is a potential for increased risk of adverse events with the drugs and herbal supplements listed in the addendum (See Addendum on pages 24 and 25)
  • The coordinator/investigator will have a discussion with the family about the use of any of the medications and herbal supplements listed in the addendum to make sure they understand the increased risk of their use and the need to contact the investigators prior to using any of the listed medications and herbal supplements.

Exclusion Criteria:

1. History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded.
2. Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged Tc (QTc> 450 milliseconds for males, QTc>470 milliseconds for females).
3. Clinically significant electrolyte disorders.
4. Gastrointestinal hemorrhage or obstruction
5. Presence of a prolactinoma (prolactin-releasing pituitary tumor).
6. Pregnant or breast feeding female
7. Known allergy to domperidone

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

other: Overall Study

Receive domperidone 4 times a day, weight-dependent dose

Interventions

Domperidone

Domperidone taken 4 times a day, dose based on body weight

Primary outcome measure

  • Change in disease severity [ Time Frame: Up to 1 year ]

Central Contacts and Locations

Central contacts

Corey Schurman, MA, CCRC

816-302-3076crschurman@cmh.edu

Locations

Children's Mercy Hospitals and Clinics

Recruiting

Kansas City, Missouri, United States, 64108

Contacts

Principal Investigator:

Jose Cocjin, MD

More Information

Sponsor

Jose Cocjin

Last update posted

Mar 24, 2026

Last verified

Mar, 2026

Keywords

  • reflux
  • acid reflux

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Jose Cocjin on 2026-03-24.